Shortridge Emily, Donatucci Craig, Donga Prina, Marcus Michael, Wade Rolin L
1 Eli Lilly and Company, Indianapolis, IN, USA.
2 IMS Health, Plymouth Meeting, PA, USA.
Am J Mens Health. 2017 Jan;11(1):164-169. doi: 10.1177/1557988315616676. Epub 2016 Jun 22.
Medication adherence and persistence patterns among patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) were analyzed. Electronic medical records of patients from the Reliant Medical Group were examined to evaluate adherence and persistence patterns. A total of 1,807 patients with LUTS/BPH were included in the study, and the number of patients at least 50 years of age was 1,748/1,807 (97%). Overall, 15.77% of patients were prescribed index prescription once, and no patients on combination alpha-blocker and 5-alpha reductase inhibitor therapies were prescribed their index prescriptions once. For all patients with LUTS/BPH, the mean number of prescriptions filled was 6.26, and the percentage of men persisting on index therapy for ≥4 years was 48%. Patients with LUTS/BPH showed a high proportion of both adherent and persistent treatment patterns, especially among patients taking combination therapy. The long follow-up time in our study provides evidence that patients are experiencing sufficient symptom relief to tolerate the challenges of remaining adherent and persistent.
对下尿路症状/良性前列腺增生（LUTS/BPH）患者的药物依从性和持续性模式进行了分析。研究人员检查了瑞联医疗集团患者的电子病历，以评估依从性和持续性模式。共有1807例LUTS/BPH患者纳入研究，其中至少50岁的患者有1748例/1807例（97%）。总体而言，15.77%的患者仅开具过一次索引处方，接受α受体阻滞剂和5α还原酶抑制剂联合治疗的患者中，无一人仅开具过一次索引处方。对于所有LUTS/BPH患者，平均取药次数为6.26次，坚持索引治疗≥4年的男性比例为48%。LUTS/BPH患者的依从性和持续性治疗模式比例较高，尤其是在接受联合治疗的患者中。我们研究中的长期随访时间表明，患者症状得到了充分缓解，能够承受坚持治疗的挑战。
